Melbourne, 1 September 2023: Opal Biosciences Limited (“Opal”) today announced its Information Memorandum to raise up to $2.5 million through the issue of 10,000,000 new Shares at $0.25 (25 cents) per share together with one (1) free attaching Option for every one (1) new Share having an exercise price of $0.25 (25 cents) and expiring […]
Melbourne, 9 August 2023: Infectious disease therapy and vaccine development company BioDiem Ltd today announced a change to its board of directors with the retirement of Mr Fergus Mak Po Kan who joined the BioDiem board in September 2021. BioDiem’s chairman Mr Damien Hannes said “We would like to express the company’s gratitude for the […]
Company Update and EOFY 2023 Information Melbourne, 4 Aug 2023: Australian vaccine development company BioDiem Ltd today and its subsidiary company Opal Biosciences Ltd (“Opal”) are pleased to provide the following update. Live attenuated flu virus (LAIV) vaccine China-based Changchun BCHT Biotechnology Co (BCHT) holds an exclusive licence from BioDiem for the vaccine technology based […]
Opal Biosciences awarded Investment Attraction Fund grant by WA government Melbourne, 18 July 2023: Australian pharmaceutical development company Opal Biosciences Limited (“Opal”) is pleased to announce it has been awarded an Investment Attraction Fund grant of $5m by the Government of Western Australia (WA). The grant will support establishment of a manufacturing facility in Perth […]
Proposed acquisition of specialist formulation company Formulytica Melbourne, 21 June 2023: Opal Biosciences Limited (“Opal”) is pleased to announce its proposed merger with specialist company, Formulytica Pty Ltd (“Formulytica”). Opal and Formulytica have partnered to establish a new sterile pharmaceutical development and manufacturing facility. The new facility will be focused on small scale product manufacture […]
BioDiem 2022 AGM Results of AGM CEO Presentation Chairman’s Address
Highlights: • LAIV flu vaccine royalty receipt • Progress in Opal’s bid to secure lease to GSK Boronia manufacturing plant • EOFY 2021 share price information Read the full annoucement
Opal acquisition of Formulytica – Capital raising
Opal Biosciences 2021 Information Memorandum
Opal announces acquisition of specialist formulation company Formulytica
BioDiem Annual Report 2020 Notice of Annual General Meeting – Explanatory Statement and Proxy Form
Launch of LAIV Flu vaccine in China Melbourne, 25 August 2020: Australian vaccine development company BioDiem Ltd is pleased to announce the product launch of Changchun BCHT Biotechnology Co (BCHT)’s LAIV vaccine in China. This is a major milestone for BCHT and for BioDiem. BCHT is BioDiem’s licencee for the LAIV flu vaccine technology in […]
BioDiem Releases Half Year Results Half-year Financial Report
Read the announcement: LAIV Influenza Vaccine Approved in China Melbourne
AGM Results Chaiman’s Address 2019 AGM Presentation
BioDiem 2019 AGM Notice of Meeting and Proxy Form
Company Update and EOFY 2019 Information
BioDiem Half Year Results – 31 December 2018
Half-year Financial Report – 31 December 2018
2018 BioDiem Annual Report Notice of Annual General Meeting and Explanatory Statement and Proxy Form
Infectious disease therapy and vaccine development company BioDiem Ltd and its subsidiary company Opal Biosciences Ltd (“Opal”) are pleased to provide the following information.
Opal Biosciences Limited announces its Information Memorandum
BioDiem receives Innovation Connections grant for Opal work
Opal BioSciences – Half-year Results Opal Biosciences Limited – Half-year Financial Report 31 Dec 2017
BioDiem Limited – Half-year Financial Report 31 Dec 2017 BioDiem Limited – Half-year Results
Read the full announcement: Opal: Completion of Placement and Board change
Read the full announcement: Scedosporium patent grant in US and Europe
Receipt of 2017 Income Tax Return Refund
2017 Notice of Annual General Meeting – Explanatory Statement
BioDiem_OPAL Update and EOFY information
20170522 Receipt of 2016 Income Tax Return Refund (BioDiem)
Opal Biosciences Annual Report 2016 Opal Biosciences Notice of Meeting and proxy form 2016 For more information, visit www.opalbiosciences.com
BioDiem Notice of Annual General Meeting and Proxy form 2016
Completion of Entitlement Offer and Issue of Convertible Preference Shares
Non-renounceable pro rata Entitlement Offer
ENTITLEMENT OFFER REPLACEMENT PROSPECTUS By accessing the BioDiem Limited Entitlement Offer Prospectus contained on this website (a copy of which has been lodged with ASIC), you must acknowledge the following terms and agree to be bound by them: A copy of this Prospectus was lodged with ASIC on 6 June 2016. Neither ASIC nor […]
BDM-I Presentation at European Clinical Conference
Influenza Vaccine Clinical Trial commences in China
BioDiem/Opal Biosciences Investor presentation at Wholesale Investor
Completion of Non-renounceable Entitlement Offer and Issue of Entitlement and Shortfall Shares
Appointment of Prof Li to the BioDiem board
Receipt of 2015 Income Tax Return Refund (BioDiem) – (FINAL)
Rights Issue Closure and Results Announcement – (FINAL)
BioDiem is presented at Wholesale Investor, Sydney
BioDiem Rights Issue and BioDiem Entitlement Offer Prospectus
BioDiem is presented at Wholesale Investor, Melbourne
ENTITLEMENT OFFER PROSPECTUS By accessing the BioDiem Limited Entitlement Offer Prospectus contained on this website (a copy of which has been lodged with ASIC), you must acknowledge the following terms and agree to be bound by them: A copy of this Prospectus was lodged with ASIC on 17 November 2015. Neither ASIC nor its officers […]
New European patents for Opal Biosciences antimicrobial, BDM-I
NasovacS WHO PreQualification certification
Chinese FDA gives approval to start LAIV vaccine clinical trials
BioDiem Notice of Annual General Meeting and Proxy form 2015
Opal’s technology presented at the Australian Society for Microbiology Annual Meeting
Opal Biosciences article in The Australian newspaper 13th July 2015
Successful grant for BDM-I – Griffith University
Opal Biosciences Investor Briefing, Melbourne 14 July 2015
Opal Biosciences Investor Briefing, Sydney 13 July 2015
Opal Biociences’ anti-infective technology profiled at 2015 Bio International Convention
Shareholder Update; Opal Biosciences
Notice of extension of exercise period for BioDiem options to 13th February 2015
Extension of BDM option exercise closing date
New Japanese patent for antimicrobial BDM-I
Wholesale Investor’s Sydney Capital Showcase and Australia Biotech Invest, Melbourne.
BioDiem CEO appointed Chairman of Ausbiotech
